A disciplined, highly targeted approach to discovering new cancer medicines
Rigorous, definitive clinical trials based on deep oncology expertise
Committed to bringing differentiated new cancer medicines to patients
ARIAD's first internally discovered and developed medicine
ARIAD Announces First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)
ARIAD Reports Second Quarter 2015 Financial Results and Progress on Strategic Objectives
A shared commitment to patients and each other. This is ARIAD.